Gilead Sciences (NASDAQ:GILD) Price Target Cut to $146.00 by Analysts at Leerink Partners

Gilead Sciences (NASDAQ:GILD) had its price target reduced by Leerink Partners from $148.00 to $146.00 in a report issued on Friday,MarketScreener reports.

Other equities research analysts have also recently issued research reports about the stock. Cantor Fitzgerald lowered their target price on shares of Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, April 10th. Oppenheimer boosted their target price on shares of Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Citigroup boosted their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a report on Monday, April 13th. Finally, Bank of America set a $162.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, February 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $157.15.

Gilead Sciences Trading Down 2.0%

NASDAQ:GILD opened at $131.33 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The stock has a market capitalization of $163.01 billion, a PE ratio of 17.89, a price-to-earnings-growth ratio of 1.77 and a beta of 0.31. The firm’s 50 day moving average is $139.59 and its 200 day moving average is $132.87. Gilead Sciences has a 12 month low of $96.18 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 49.45%. Gilead Sciences’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts expect that Gilead Sciences will post 8.62 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s payout ratio is 48.45%.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the transaction, the chief executive officer directly owned 632,567 shares in the company, valued at approximately $81,702,353.72. The trade was a 1.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the completion of the transaction, the chief financial officer owned 167,779 shares of the company’s stock, valued at $25,910,110.97. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 63,000 shares of company stock worth $9,238,250 in the last three months. Corporate insiders own 0.30% of the company’s stock.

Institutional Trading of Gilead Sciences

Institutional investors have recently added to or reduced their stakes in the business. Strategic Investment Solutions Inc. IL purchased a new stake in Gilead Sciences during the fourth quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC boosted its position in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares during the period. Corundum Trust Company INC purchased a new stake in Gilead Sciences during the third quarter valued at about $26,000. Quattro Advisors LLC purchased a new stake in Gilead Sciences during the fourth quarter valued at about $26,000. Finally, Wealth Preservation Advisors LLC boosted its position in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 81 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Truist Financial reaffirmed its buy rating on Gilead and raised its price target to $157 from $155, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: Gilead reported Q1 EPS of $2.03 and revenue of $6.96 billion, both ahead of analyst expectations, supported by HIV and Trodelvy sales growth. Yahoo Finance
• Positive Sentiment: The company raised its Yeztugo 2026 sales guidance to $1 billion from $800 million, signaling stronger-than-expected launch momentum. Yahoo Finance
• Neutral Sentiment: RBC slightly reduced its price target to $122 from $123 and kept a sector perform view, suggesting a more cautious stance but no major change in thesis. Benzinga
• Negative Sentiment: Gilead cut its 2026 EPS guidance to a loss range of -$1.05 to -$0.65, a major deterioration from prior profit expectations, due to acquisition charges and financing costs. Reuters
• Negative Sentiment: Investors also appear concerned that near-term growth is being driven more by older products like Descovy and Biktarvy than by the much-anticipated Yeztugo launch, creating questions about the pace of future growth. Yahoo Finance

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.